Drug Trial Radar · NCT06838143
Ilaris NIS in Korea
Last checked: Nov 20, 2026Latest source record: May 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
25
Planned (sponsor's estimate)
Start
Mar 29, 2025
Primary completion
Sep 30, 2028
Study completion Sep 30, 2028
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Feb 20, 2025
Design
- Study type
- Observational
- Who can join
- All sexes, from 2 years, up to 100 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a study to evaluate safety and effectiveness of Ilaris in adult and pediatric patients receiving the drug in a clinical setting for any of the following indications, Hereditary Periodic Fever Syndromes, Cryopyrin-associated periodic syndromes (CAPS), colchicine resistance familial Mediterranean fever (crFMF), TNF receptor associated periodic syndrome (TRAPS), Hyper-IgD syndrome / Mevalonate kinase deficiency (HIDS/MKD) or Systemic juvenile idiopathic arthritis (sJIA).
Conditions
- Hereditary Periodic Fever Syndromes
- Cryopyrin-associated Periodic Syndromes (CAPS)
- Colchicine Resistance Familial Mediterranean Fever (crFMF)
- TNF Receptor Associated Periodic Syndrome (TRAPS)
- Hyper-IgD Syndrome / Mevalonate Kinase Deficiency (HIDS/MKD)
- Systemic Juvenile Idiopathic Arthritis (sJIA)
Interventions
IlarisBiological
Prospective observational study. There is no treatment allocation.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of adverse events and serious adverse eventsTime frame: Up to 104 weeks from Ilaris treatment
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Novartis Investigative Site
Seoul, South Korea · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.